Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EFPIA Calls For Increased EU Collaboration Ahead Of European Elections

This article was originally published in The Pink Sheet Daily

Executive Summary

EFPIA’s call for more integration in approaches to some areas of health care ahead of the European Parliamentary elections in May could benefit research.

You may also be interested in...



European Notebook: Price Cuts Planned In France; IPO Window Thrown Open; European Big Pharmas Pursue Major Deals

Increased optimism about economic growth in Europe has been followed by IPOs becoming more common among the region’s biotech companies; there’s a speculation frenzy about M&A; and with European parliamentary elections in May, further regulatory and legislative changes are likely later in the year.

European Notebook: IPO Fever Comes To Europe; EMA Plans Adaptive Licensing Pilot Project

Pharmaceutical and biotech companies in Europe take heart from IPOs and new governmental schemes to improve patients’ early access to innovative medicines, while fresh calls are made for an integrated, over-arching European industrial strategy for the life sciences sector.

Public-Private Partnerships Like IMI Crucial to Industry's Future, Argue Leaders

Public-private partnerships like Europe's Innovative Medicines Initiative, the EU’s mechanism that promotes new treatment R&D, are crucial to the industry's future, according to Paul Stoffels, Chairman global R&D pharmaceuticals at Johnson & Johnson.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS076965

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel